Evidence map›Paper›PMID 29246310›Full record

ArticleMolecular therapy. Nucleic acids2017

Inhibition of Murine Cytomegalovirus Infection in Animals by RNase P-Associated External Guide Sequences.

Wei Li, Jingxue Sheng, Mengqiong Xu, Gia-Phong Vu, Zhu Yang, Yujun Liu, Xu Sun, Phong Trang, Sangwei Lu, Fenyong Liu

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Wei LiDepartment of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China.
Jingxue ShengProgram in Comparative Biochemistry, University of California, Berkeley, Berkeley, CA 94720, USA; School of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA.
Mengqiong XuDepartment of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China.
Gia-Phong VuSchool of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA.
Zhu YangJiangsu Affynigen Biotechnolgies, Inc., Taizhou, Jiangsu 225300, China; Guangzhou Qinheli Biotechnolgies, Inc., Guangzhou, Guangdong 510600, China.
Yujun LiuDepartment of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China; School of Medicine, St. George's University, Grenada, West Indies; School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
Xu SunDepartment of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China; Guangzhou Qinheli Biotechnolgies, Inc., Guangzhou, Guangdong 510600, China.
Phong TrangProgram in Comparative Biochemistry, University of California, Berkeley, Berkeley, CA 94720, USA.
Sangwei LuProgram in Comparative Biochemistry, University of California, Berkeley, Berkeley, CA 94720, USA; School of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA.
Fenyong LiuDepartment of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China; Program in Comparative Biochemistry, University of California, Berkeley, Berkeley, CA 94720, USA; School of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA. Electronic address: liu_fy@berkeley.edu.
Jinan University · CNUniversity of California, Berkeley · USShandong University of Traditional Chinese Medicine · CN

Funding

RIBOZYMES FOR STUDIES AND TREATMENT OF HCMV INFECTIONSR01AI041927 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 1997 to 2012
$3.7M
Persistent infection of human cytomegalovirus in oral mucosaR01DE025462 · NIDCR · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2015 to 2019
$2.3M
Human cytomegalovirus chromatin modifications in oral infectionR01DE023935 · NIDCR · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2013 to 2017
$2.3M
Bacteria Based Agents for Therapy of AIDS Associated InfectionsR01AI091536 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LU, SANGWEI · 2011 to 2014
$1.3M
NIAID NIH HHS R01 AI041927NIAID NIH HHS R01 AI091536NIDCR NIH HHS R01 DE023935NIDCR NIH HHS R01 DE025462
6 · The paper itself

Abstract

External guide sequence (EGS) RNAs are associated with ribonuclease P (RNase P), a tRNA processing enzyme, and represent promising agents for gene-targeting applications as they can direct RNase-P-mediated cleavage of a target mRNA. Using murine cytomegalovirus (MCMV) as a model system, we examined the antiviral effects of an EGS variant, which was engineered using in vitro selection procedures. EGSs were used to target the shared mRNA region of MCMV capsid scaffolding protein (mCSP) and assemblin. In vitro, the EGS variant was 60 times more active in directing RNase P cleavage of the target mRNA than the EGS originating from a natural tRNA. In MCMV-infected cells, the variant reduced mCSP expression by 92% and inhibited viral growth by 8,000-fold. In MCMV-infected mice hydrodynamically transfected with EGS-expressing constructs, the EGS variant was more effective in reducing mCSP expression, decreasing viral production, and enhancing animal survival than the EGS originating from a natural tRNA. These results provide direct evidence that engineered EGS variants with higher targeting activity in vitro are also more effective in reducing gene expression in animals. Furthermore, our findings imply the possibility of engineering potent EGS variants for therapy of viral infections.

Indexed as

antisensegene targetinggene therapyherpesvirusRNase P

Identifiers

PMID29246310
PMCPMC5684469
OpenAlexW2766238164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.